Green-Lipped Mussel (Perna canaliculus)
Green-lipped mussel (Perna canaliculus) is a New-Zealand-endemic bivalve commercially supplemented as freeze-dried whole-mussel powder or as the patented stable lipid fraction (Lyprinol® / Pernaette®). The compositional interest sits in its long-chain marine omega-3 fraction (EPA, DHA, and the unusual ETA / OTA), glycosaminoglycans (chondroitin sulphate analogues), and the lipid fraction's furan fatty acids. Joint-comfort positioning derives from older clinical trials; a 2008 systematic review (Brien et al., QJM) found a positive but unconfirmed signal from small trials. NO authorised UK food-supplement health claims are tied to "green-lipped mussel" as such. Shellfish allergen warning is mandatory; antiplatelet potential warrants disclosure to anticoagulation teams. Pregnancy: avoid supplemental forms.
Camden Medicals editorial · Last reviewed 4 May 2026 · Next review November 2026
- Cross-checked against
- NHS
- NICE
- BNF
- EFSA
- FSA
Camden's editorial team independently graded each health claim below on the strength of the published evidence — see the grade beside every condition.
- Class
- Other
- Top use evidence
- Limited
On this page
What it is
Green-lipped mussel (Perna canaliculus) is a marine bivalve endemic to the coastal waters of New Zealand. Commercial supplements derive from the whole mussel meat — typically aquacultured rather than wild-caught — processed by either of two main routes. The simpler, lower-cost route freezes and powders the whole mussel, yielding a beige-to-pale-green powder rich in protein, glycosaminoglycans (including chondroitin sulphate), and a lipid fraction containing long-chain omega-3 fatty acids. The premium route uses supercritical CO₂ extraction of the lipid fraction to produce a stable concentrate marketed under brand names such as Lyprinol® / Pernaette® / Seatone®; these branded extracts concentrate the omega-3 and furan-fatty- acid fractions and remove most of the protein content.
The compositional point of interest, distinguishing GLM from generic fish oil, is the presence of eicosatetraenoic acid (ETA, 20:4 n-3) and octadecatetraenoic acid (OTA, 18:4 n-3) in addition to the more familiar EPA and DHA. ETA is uncommon in the wider human diet — most fish oils have negligible ETA — and pre-clinical work attributes much of the observational anti- inflammatory signal of GLM lipid extracts to the ETA fraction via 5-lipoxygenase pathway modulation. The translation from pre-clinical mechanism to human clinical-outcome trials is the long-standing weak link.
Regulatory note: green-lipped mussel as a food and food supplement ingredient is lawful in the UK; it is not a UK novel food. There are NO EFSA-authorised health claims under Regulation 1924/2006 (retained) for "green-lipped mussel" as such. UK marketing copy must therefore avoid joint-health, arthritis-relief, and inflammation-specific claim language. The EPA / DHA-anchored authorised claims (heart, brain, vision) apply only at the dosing thresholds defined in the GB Nutrition and Health Claims Register — typical GLM capsules deliver EPA+DHA an order of magnitude below those thresholds and so cannot rely on those claim wordings.
At a glance
- A New-Zealand-endemic bivalve (Perna canaliculus) supplemented either as freeze-dried whole-mussel powder or as the patented stable lipid extract (Lyprinol®, Pernaette®). The two preparations have different per-mg compositions and should not be assumed equivalent.
- NO authorised UK food-supplement health claims attach to "green-lipped mussel" as a substance. The marine omega-3 fraction (EPA + DHA) carries authorised claims at ≥250 mg/day combined intake, but typical 500 mg GLM capsules deliver <50 mg combined EPA+DHA — far below that threshold.
- Compositional differentiator from fish oil: GLM contains eicosatetraenoic acid (ETA) and octadecatetraenoic acid (OTA) in addition to EPA and DHA. The lipid extract Lyprinol® concentrates these. ETA in particular is uncommon in the wider human diet; pre-clinical work attributes the observational anti-inflammatory signal to the ETA fraction, although translation to human clinical-outcome trials is mixed.
- Joint-comfort evidence is older and mixed. A 2008 systematic review of GLM in osteoarthritis (Brien et al., QJM) re-analysed four RCTs and found GLM may be superior to placebo for mild-to-moderate OA, but the trials were small and the authors called for larger studies. UK marketing must therefore stay descriptive rather than invoke clinical-claim language.
- Shellfish allergen — mussel is a Category-14 UK FIC declared allergen. Customers with shellfish allergy MUST avoid GLM. Cross-reactivity with crustacean allergy is partial but documented; conservative reading is to avoid all shellfish products if any shellfish allergy is known.
- Antiplatelet interaction — the EPA/DHA + ETA fraction inhibits platelet aggregation at supplement doses. Disclose use to your prescriber if you take warfarin, DOACs, aspirin, clopidogrel, or NSAIDs.
- Pregnancy and breastfeeding: avoid supplemental forms. Marine-source supplements have variable mercury / heavy-metal exposure; finished-product CoA on heavy metals is the relevant disclosure.
What people use it for
Adults with mild joint discomfort exploring alternatives to glucosamine and chondroitin
Green-lipped mussel offers a different compositional profile from glucosamine and chondroitin alone — a marine omega-3 component (uncommon ETA fraction) plus glycosaminoglycans in one matrix. The clinical-outcome evidence is less developed than for glucosamine sulphate or chondroitin sulphate, so it is reasonably positioned as a complementary option rather than a first-line evidence-based intervention. [1]
Some evidenceLimitedAdults with shellfish-tolerated marine sourcing preference seeking an omega-3 + glycosaminoglycan blend
For customers comfortable with shellfish-source supplements, GLM provides EPA / DHA / ETA / OTA + GAGs in a single capsule — useful when the supplement-stack design favours combined-mechanism formats over multiple single-active capsules. Cardiovascular and brain-function authorised claims for EPA/DHA are not reachable at typical GLM per-day doses; if those endpoints are the reason for supplementing, fish oil at trial-comparable EPA+DHA doses is the better fit.
Some evidenceLimited
How it works
The proposed mechanisms for GLM activity in joint comfort cluster around three axes. First, the long-chain marine omega-3 fraction (EPA, DHA, ETA, OTA) competes with arachidonic acid as a substrate for cyclooxygenase and 5-lipoxygenase pathways, shifting the eicosanoid mix toward less pro-inflammatory mediators. Second, the glycosaminoglycan content (chondroitin sulphate analogues) provides substrate for cartilage-matrix turnover, paralleling the more studied chondroitin-supplement story. Third, in vitro work on the Lyprinol® lipid fraction has shown 5-LOX inhibition and reduced leukotriene B4 production at concentrations achievable in vivo at standardised supplement doses. None of these mechanisms has translated cleanly to human clinical-outcome trials of consistent quality, which is the principal reason the 2008 systematic review of GLM in osteoarthritis (Brien et al., QJM) — though it found a positive signal in the more rigorous trials — stopped short of a routine clinical recommendation and called for larger studies.
Common myths
Myth""Green-lipped mussel is a natural alternative to anti-inflammatory drugs.""
RealityThere is no UK-authorised food-supplement claim that positions green-lipped mussel as anti-inflammatory or as a substitute for medical treatment. A 2008 systematic review of GLM in osteoarthritis (Brien et al., QJM) found a positive but small-trial signal that has not since been confirmed by larger trials. People with diagnosed inflammatory arthritis should follow NICE-guided treatment under their rheumatology team — supplements are not a substitute and combining them with prescribed therapy must be discussed with the prescriber. [2,3]
Myth""GLM is the same as taking fish oil.""
RealityNot quite. GLM contains EPA and DHA but at much lower per-mg dose than typical fish oil (a 500 mg GLM capsule typically delivers ~10–40 mg combined EPA+DHA, vs ~300 mg in a 1000 mg fish oil softgel). GLM also contains the unusual ETA and OTA fractions and a glycosaminoglycan matrix that fish oil lacks. The two products serve different supplement-design purposes; substituting one for the other typically does not preserve dose-response.
Myth""Lyprinol® and generic green-lipped mussel powder are interchangeable.""
RealityThey are different preparations. Generic freeze-dried whole-mussel powder retains protein, glycosaminoglycans, and a dilute lipid fraction. Lyprinol® / Pernaette® / Seatone® are CO₂-extracted lipid concentrates that remove protein and concentrate the omega-3 + furan-fatty-acid fractions. Per mg, the lipid extracts are higher-strength on the fatty-acid axis but lower on the GAG axis. Quality marker on the label: which preparation, what extraction route, what guaranteed lipid fraction.
Myth""It's natural, so it's safe in pregnancy.""
RealityNaturalness-as-safety arguments collapse against (a) marine-source heavy-metal accumulation risk and (b) the absence of pregnancy-specific safety data on supplemental GLM. Dietary mussel intake from a varied diet is a different question from a concentrated daily supplement. Pregnancy: avoid supplemental forms. [4]
Myth""Shellfish-allergic people can usually tolerate green-lipped mussel.""
RealityNo. Mussel is a category-14 UK FIC declared allergen and cross-reactivity within the bivalve family is high. Customers with any documented mussel, oyster, or scallop allergy must avoid GLM products. Customers with crustacean (prawn, crab, lobster) allergy may have partial cross-reactivity to bivalves and conservative reading is to avoid GLM unless an allergist has explicitly cleared bivalve consumption. [5]
🔬 Camden’s evidence review
The research Camden reviewed, graded on its strength. This is our own appraisal — it sits beneath the official guidance above, never above it.
Osteoarthritis joint comfort (knee, hip)
MixedEvidencemixedA systematic review of green-lipped mussel in osteoarthritis (Brien et al., QJM, 2008) evaluated four RCTs covering freeze-dried whole-mussel and the Lyprinol® lipid fraction. After setting aside two trials for possible un-blinding and statistical flaws and re-analysing the original data, the two more rigorous trials suggested GLM may be superior to placebo for mild-to-moderate OA — but the trials were small and the authors called for further rigorous investigation of efficacy and dose. Subsequent trials have not consolidated the evidence base into a clear positive recommendation. UK supplement marketing must therefore stay descriptive of the compositional fraction (omega-3 + GAGs) rather than invoke joint-pain or arthritis claim language. NHS osteoarthritis guidance does not list GLM among recommended interventions. [2,1]
Rheumatoid arthritis symptom management
InsufficientEvidenceinsufficientOlder small trials (1980s–2000s) explored GLM in rheumatoid arthritis with conflicting results. The methodological quality is limited and reproducibility weak. NICE rheumatoid-arthritis guidance (NG100, last updated 2020) does not list GLM among non-pharmacological interventions. Marketing in this category is editorially unsafe. [3]
Asthma
InsufficientEvidenceinsufficientSmall early-2000s trials explored Lyprinol® in asthma symptom management on the 5-LOX-inhibition mechanism. The evidence base is too small to support any UK food-supplement positioning and the SIGN / BTS asthma-management guidelines do not list GLM. Asthma-positioning marketing on GLM-specific evidence is editorially unsafe. [6]
Cardiovascular and brain-function endpoints
InsufficientEvidenceinsufficientThe EPA + DHA fraction in GLM is mechanistically capable of supporting heart and brain function, but at typical per-capsule doses (~10–40 mg EPA+DHA per 500 mg GLM) the contribution falls an order of magnitude below the 250 mg/day EPA+DHA threshold the GB Nutrition and Health Claims Register defines for those authorised claims. UK supplement marketing for GLM should NOT invoke the EPA / DHA cardiovascular / cognitive claim wording — the per-day dose simply does not reach the threshold. [7]
Safety
Pregnancy and breastfeeding
Avoid supplemental green-lipped mussel in pregnancy. Marine-source supplements have variable heavy-metal exposure (cadmium in particular accumulates in bivalves), and reproductive-safety data on supplemental GLM is absent. Dietary mussel intake from a varied diet should follow NHS pregnancy food-safety guidance, which is a separate question.
Avoid supplemental green-lipped mussel during breastfeeding for the same heavy-metal-exposure reason and the absence of lactation-safety data. Maternal dietary mussel intake should follow NHS guidance.
Talk to your GP, midwife, or pharmacist before starting any supplement during pregnancy or breastfeeding.
Contraindications
- Documented mussel, oyster, scallop, or wider bivalve allergy.
- Documented crustacean (prawn / crab / lobster) allergy — partial cross-reactivity makes conservative avoidance the reasonable position pending allergist clearance.
- Use within 14 days of major surgery — antiplatelet potential of the lipid fraction warrants peri-operative pause.
Drug interactions
- Anticoagulants (warfarin, DOACs) and antiplatelets (aspirin, clopidogrel, ticagrelor, NSAIDs): the EPA / DHA / ETA fraction of GLM has antiplatelet activity at supplement doses. Disclose use to your anticoagulation team and avoid in the peri-operative window.
- Lithium: long-chain omega-3 lipids may modestly affect lithium pharmacokinetics in some individuals; monitor lithium levels if concurrent supplementation begins.
- NSAIDs (ibuprofen, naproxen, diclofenac): combined antiplatelet effect; not a contraindication but disclose at GP review.
This is not an exhaustive list. Always tell your prescriber and pharmacist about every supplement you take.
Common side effects
- Mild gastrointestinal upset (especially fishy aftertaste / belching with freeze-dried whole-mussel powder).
Rare side effects
- Allergic reaction in shellfish-sensitive individuals — ranges from mild urticaria to anaphylaxis. Stop immediately and seek medical attention if any allergic features appear.
- Headache and dizziness reported in early trials at upper doses.
- Increased bruising or bleeding tendency at higher per-day doses, particularly when combined with antiplatelet medication.
How to take it
- Timing
- Take with food to support lipid-fraction absorption. Splitting the dose across the day does not appear to confer advantage in published trials.
How to spot quality
Look for
- Source country declared as New Zealand (Perna canaliculus is endemic; non-NZ "green mussel" preparations may be Perna viridis, a different species with a different compositional profile and a less-developed evidence base).
- Preparation route declared on label and CoA: freeze-dried whole-mussel powder (commodity tier) or CO₂-extracted lipid concentrate / Lyprinol® / Pernaette® (premium tier). The two are not interchangeable.
- Heavy-metal panel on the CoA — bivalves bioaccumulate cadmium, mercury, and lead. EC Regulation 629/2008 (retained in GB) sets a 1.0 mg/kg wet-weight cadmium maximum on bivalve molluscs; supplement-grade material should sit below that. Mercury and lead panels should also appear.
- Allergen declaration: mussel must appear in the ingredient list in bold (UK FIC 14-allergen list). Manufacturing-facility cross-contamination disclosure for other shellfish is good practice.
- Stabilisation strategy disclosed for Lyprinol®-style lipid extracts — the omega-3 fraction is oxidation-prone; rosemary extract, mixed tocopherols, or ascorbyl palmitate as antioxidant carriers signal serious formulation. A peroxide-value or TOTOX figure on the CoA is the gold-standard quality marker.
- Country of cultivation and aquaculture-vs-wild-caught disclosure — most commercial NZ GLM is aquacultured (Marlborough Sounds region); aquaculture provenance is generally cleaner on heavy-metal exposure than wild bivalves from coastal-runoff zones.
Red flags
- Generic "Green-lipped mussel Xmg" with no source country, no preparation-route declaration, and no heavy-metal panel.
- Joint-pain, arthritis, or anti-inflammatory marketing language not authorised under UK Regulation 1924/2006 (none exist for GLM).
- EPA / DHA-anchored cardiovascular or cognitive claim language at per-day doses below the 250 mg EPA+DHA / day threshold required for those claims.
- Absence of allergen declaration or "may contain shellfish" wording on the consumer-facing label.
- Use of Perna viridis (Asian green mussel) labelled as "green-lipped mussel" without species-disambiguation — Perna viridis is a different species with a distinct evidence base and different bioaccumulation pattern.
Commonly combined with
Other ingredients that share a biological pathway, cofactor relationship, or evidence-backed protocol with this one. Mechanisms below cite primary physiology — not folk pairing. Doses are literature ranges, not recommendations. Talk to your pharmacist or GP before changing your stack, especially if you take prescription medication.
Fish Oil (Long-Chain Omega-3 EPA / DHA, Marine Source)
Limited evidenceOmega-3 cluster — GLM Lyprinol + fish oil — different EPA / DHA delivery contexts.
GLM Lyprinol is a CO2-extracted lipid-fraction with EPA / DHA + ETA + furanoid acids (anti-inflammatory profile). Fish oil bulk EPA / DHA. Different lipid extracts; mechanism overlapping on anti-inflammatory axis.
Evidence: Camden green-lipped-mussel + fish-oil entries cover cluster.
Doses studied: 1000 mg GLM extract + 1000-2000 mg fish oil daily.
Glucosamine
Limited evidenceJoint-cluster pairing — GLM + glucosamine combination products (Brien 2008 QJM review — small-trial evidence).
GLM lipid anti-inflammatory + glucosamine GAG substrate. Different mechanisms; complementary.
Evidence: Camden glucosamine covers cluster.
Doses studied: 1000 mg GLM extract + 1500 mg glucosamine sulphate daily.
Chondroitin Sulphate
Limited evidenceJoint-cluster pairing — see glucosamine and GLM.
Chondroitin sulphate matrix component + GLM lipid anti-inflammatory.
Evidence: Joint-cluster co-formulation.
Doses studied: 1000 mg GLM + 1200 mg chondroitin daily.